| 降钙素基因相关肽受体拮抗剂—Ubrogepent的研究进展 |
| |
| 引用本文： | 赵爽,陈红英,苗秋丽,刘伟兵,宋燕青. 降钙素基因相关肽受体拮抗剂—Ubrogepent的研究进展[J]. 中国药物警戒, 2021, 0(3): 289-293 |
| |
| 作者姓名： | 赵爽 陈红英 苗秋丽 刘伟兵 宋燕青 |
| |
| 作者单位： | 吉林大学第一医院药学部 |
| |
| 基金项目： | 国家重点研发计划(2016YFC1303804)。 |
| |
| 摘 要： | 降钙素基因相关肽受体拮抗剂ubrogepant是一种口服、小分子、高选择性、降钙素基因相关肽受体拮抗剂.抑制降钙素基因相关肽(CGRP)的活性而发挥作用.与传统治疗偏头痛急性期的药物相比,ubrogepant可以有效预防急性偏头痛的发作,减少发作次数,且有良好的耐受性和较少的禁忌证.通过对ubrogepant的作用机制...
|
| 关 键 词： | 降钙素基因相关肽受体拮抗剂 ubrogepant 急性偏头痛 小分子口服药物 |
Research Progress in Ubrogepant |
| |
| ZHAO Shuang,CHEN Hongying,MIAO Qiuli,LIU Weibing,SONG Yanqing. Research Progress in Ubrogepant[J]. Chinese JOurnal of Pharmacovigilance, 2021, 0(3): 289-293 |
| |
| Authors: | ZHAO Shuang CHEN Hongying MIAO Qiuli LIU Weibing SONG Yanqing |
| |
| Affiliation: | (Department of Pharmacy,the First Hospital of Jilin University,Changchun Jilin 130021,China) |
| |
| Abstract: | Ubrogepant(trade name:Ubralvy)is an oral,small molecule,highly selective,calcitonin generelated peptide receptor antagonist(CGRP P-receptor),which won the first approval of FDA for the treatment of episodic migraine by inhibiting CRGP activity.Compared with conventional drugs for acute migraine,ubrogepant can prevent the episode of acute migraine and reduce the number of episodes,which is better tolerated and has fewer contraindications.This article reviews the mechanism,pharmacokinetics,pharmacodynamics,clinical evaluation and safety of ubrogepant in order toprovide reference for clinical treatment and further research. |
| |
| Keywords: | ubrogepant acute migraine small molecule oral medicine |
| 本文献已被 维普 等数据库收录！ |
|
